AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

ALOGLIPTIN 12.5 Mg ;

9 registrations across 1 African market— 9 active

Markets with ALOGLIPTIN 12.5 Mg ;

Recent registrations

Brand / ProductMarketHolderStatusExpires
Adwiagliptin 12.5mg
Film Coated Tablets
🇪🇬EgyptAdwiaactive
Gliptopack 12.5 mg
Film Coated Tablets
🇪🇬EgyptGlobal Advanced pharmaceuticals "GAP"active
Adwiagliptin 12.5mg
Film Coated Tablets
🇪🇬EgyptAdwiaactive
Gliptopack 12.5 mg
Film Coated Tablets
🇪🇬EgyptGlobal Advanced pharmaceuticals "GAP"active
Gliptawest
Film Coated Tablets
🇪🇬EgyptWestern Pharmaceuticals Industriesactive
Aloglipt 12.5 mg
Film Coated Tablets
🇪🇬EgyptInternational drug agency for pharmaceutical industry (IDI)active
Prandaglim 12.5 mg
Film Coated Tablets
🇪🇬EgyptEva pharma for Pharmaceuticals and Medical Appliances - Eva Pharmaactive
Gliptawest
Film Coated Tablets
🇪🇬EgyptWestern Pharmaceuticals Industriesactive
Prandaglim 12.5 mg
Film Coated Tablets
🇪🇬EgyptEva pharma for Pharmaceuticals and Medical Appliances - Eva Pharmaactive

ALOGLIPTIN 12.5 Mg ; in Africa — Regulatory Overview

ALOGLIPTIN 12.5 Mg ; is registered across 1 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Egypt. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 9 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.